Just - Evotec Biologics
401 Terry Avenue North
About Just - Evotec Biologics
Just - Evotec Biologics, is a unique platform company that integrates the design, engineering, development, and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus is to create access and value for a global market through scientific and technological innovation. Learn more at www.just.bio.
29 articles about Just - Evotec Biologics
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
Evotec SE and Sandoz AG, a division of Novartis announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.
Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer
Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development Officer.
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
Sernova Corp. announced the presentation of preclinical data supporting the anticipated 2024 IND submission and planned Phase 1/2 clinical trial of Evotec SE’s iPSC-derived ILCs in combination with Sernova’s implantable Cell Pouch device for the treatment of patients with T1D.
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
Evotec SE reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
Evotec SE announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016.
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis.
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Evotec SE announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
Evotec Receives € 150 m Loan from European Investment Bank
Evotec SE and the European Investment Bank announced that the EIB has granted Evotec an unsecured loan facility of € 150 m to support the Company's R&D activities, equity investments and the building of the new J.POD ® biologics manufacturing facility on Evotec's Campus Curie in Toulouse, France.
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
Evotec SE announced that the Company has extended and expanded its integrated multi-target drug discovery agreement with data-driven biotech creation firm, Related Sciences, to continue to grow their joint portfolio of drug development candidates through 2030, leveraging Evotec's industry-leading capabilities across the full R&D continuum.
Evotec Completes Acquisition of Central Glass Germany
Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
Evotec SE presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access.
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases
Evotec SE announced that the Company has entered a partnership with Hannover Medical School, one of the leading German universities, to generate a molecular patient database for Sjögren's syndrome and systemic lupus erythematosus.
This week's money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
Evotec SE announced that the U.S. Department of Defense has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody -based drug product prototypes targeting plague.
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
Other non-operating result of € (89.8) m (H1 2021: € 106.1 m) explained by the non-cash fair value adjustments of the equity investment in publicly listed Exscientia plc.
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
Evotec SE and Alpine Immune Sciences, Inc. announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.
Evotec SE Reports First Half-year 2022 Results on 11 August 2022
Evotec SE will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022.
Evotec SE Reports Results of Annual General Meeting 2022
In a presentation titled "Reaching the goal with higher speed and confidence", CEO Dr Werner Lanthaler and CFO Enno Spillner presented Evotec SE's current strategic, scientific and technological developments, highlights of the 2021 business year and the commitment to sustainability/ESG.